AL3818
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for AL3818, covering 2023-11-08 to 2025-02-24. Get the full timeline:
Most recent: Clinical Trial Update: Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors [Phase 1, Phase 2]